ClinicalTrials.gg
TerminatedNCT05274451Updated Jul 1, 2025

A Study to Investigate LYL797 in Adults With Solid Tumors

A Phase 1 interventional study of LYL797 in Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer and Non-small Cell Lung Cancer, sponsored by Lyell Immunopharma, Inc.. Terminated at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-01.

Primary conditionnone(registry's first term: Triple Negative Breast Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Triple Negative Breast Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Lyell Immunopharma, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Pipeline Reprioritization

From the registry’s dates

  • Primary completion was Nov 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-resistant epithelial ovarian cancer/ fallopian tube cancer/ primary peritoneal cancer (Ovarian cancer), or Endometrial cancer. The first part of the study will determine the safe dose for the next part of the study, and will enroll patients with TNBC, NSCLC, Ovarian or Endometrial cancer. The second part of the study will test that dose in additional patients with TNBC, NSCLC, Ovarian or Endometrial cancer.

Read the detailed description

This Phase 1, single-arm, open-label, multi-center, dose-escalation and expansion study will evaluate the safety and tolerability of LYL797, ROR1- targeted CAR T cells, in adults with relapsed and/or refractory ROR1+ triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), Ovarian cancer, or endometrial cancer. The dose-escalation phase includes patients with TNBC, NSCLC, Ovarian, or Endometrial cancer, and will investigate multiple dose levels to identify the recommended Phase 2 dose (RP2D). The dose-expansion phase will enroll patients with TNBC, NSCLC, Ovarian, or Endometrial cancer at the RP2D.

02

Conditions studied

  • Triple Negative Breast Cancer
  • TNBC - Triple-Negative Breast Cancer
  • Non-small Cell Lung Cancer
  • Non Small Cell Lung Cancer
  • Non Small Cell Lung Cancer Metastatic
  • Non-Small Cell Carcinoma of Lung, TNM Stage 4
  • Advanced Breast Cancer
  • Advanced Lung Carcinoma
  • NSCLC
  • NSCLC, Recurrent
  • NSCLC Stage IV
  • Relapsed Cancer
  • Relapse/Recurrence
  • Recurrent Breast Cancer
  • Recurrent NSCLC
  • Platinum-resistant Ovarian Cancer
  • Ovarian Cancer
  • Primary Peritoneal Carcinoma
  • Fallopian Tube Cancer
  • Endometrial Cancer
  • Endometrioid Tumor
  • High Grade Serous Carcinoma
  • Ovarian Epithelial Cancer

Keywords

  • CAR T-cell therapy
  • CAR T
  • CAR T-cell
  • CAR-T
  • CAR-T cell therapy
  • CAR-T cell
  • ROR1
  • ROR1+
  • ROR1 positive
  • cell therapy
  • immunotherapy
  • relapsed
  • refractory
  • solid tumor
  • advanced
  • metastatic
  • breast cancer
  • lung cancer
  • triple negative breast cancer
  • non small cell lung cancer
  • ovarian cancer
  • endometrial cancer
03

In context

Lead sponsor

Lyell Immunopharma, Inc. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

IInclusion Criteria:

  • ≥ 18 years of age at time of
  • Confirmation of ROR1 expression from a pretreatment tumor sample
  • confirmed TNBC or NSCLC that is , or locally advanced and unresectable
  • Platinum-resistant epithelial ovarian cancer/ fallopian tube cancer/ primary peritoneal cancer.
  • Endometrial cancer.
  • including a target lesion and an additional lesion for
  • (ECOG) performance status 0 or 1
  • Adequate organ and marrow function
  • Women of must have a negative pregnancy test at screening
  • All participants must agree to practice highly effective methods of

Exclusion Criteria:

  • Prior treatment with any adoptive T-cell therapy or other anti-ROR1 therapy
  • Prior solid organ transplantation
  • Active, untreated or ; however, stable, treated brain metastases are allowed
  • Untreated or active infection at the time of screening or leukapheresis
  • -positive, HTLV-1-positive, active acute HAV, acute or chronic or , or active tuberculosis
  • Impaired cardiac function or cardiac disease
  • Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures (once monthly or more frequent), or lymphangitis carcinomatosis
  • History of interstitial pneumonitis or pulmonary fibrosis.
  • Systemic or other medications within 14 days of leukapheresis
  • Pregnant or lactating/nursing women
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Experimental LYL797

    ROR1-targeted CAR T cells

    Biological: LYL797

Interventions

  • BiologicalLYL797

    LYL797 is an autologous, genetically (Gen-R™) and epigenetically (Epi-R™) reprogrammed ROR1-targeted chimeric antigen receptor (CAR) T-cell therapy

06

What researchers measure

Primary outcomes

  1. Evaluate incidence of dose-limiting toxicities (DLTs)

    Incidence of dose-limiting toxicities (DLTs)

    Time frame: Up to 28 days

  2. Evaluate incidence of treatment-emergent adverse events (TEAEs)

    Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 2 years

  3. Evaluate severity of treatment-emergent adverse events (TEAEs)

    Severity of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 2 years

  4. Determine recommended Phase 2 Dose (RP2D)

    Dose-escalation phase to determine the recommended Phase 2 dose

    Time frame: Up to 2 years

Secondary outcomes

  1. Evaluate anti-tumor activity of LYL797 based on overall response rate (ORR) by RECIST, version 1.1

    Overall response rate (ORR) by RECIST, version 1.1

    Time frame: Up to 2 years

  2. Evaluate duration of response (DOR)

    Duration of response (DOR)

    Time frame: Up to 2 years

  3. Evaluate progression-free survival (PFS)

    Progression-free survival (PFS)

    Time frame: Up to 2 years

  4. Evaluate overall survival (OS)

    Overall Survival (OS)

    Time frame: Up to 2 years

  5. Evaluate maximum concentration of LYL797 (Cmax) of LYL797 in peripheral blood (PB) samples

    Maximum concentration of LYL797 (Cmax)

    Time frame: Up to 2 years

  6. Evaluate time to Cmax (Tmax) of LYL797 in peripheral blood (PB) samples

    Time to Cmax (Tmax)

    Time frame: Up to 2 years

  7. Evaluate area under the concentration-time curve (AUC) of LYL797 in the peripheral blood (PB)

    Area under the concentration-time curve (AUC)

    Time frame: Up to 2 years

  8. Evaluate Persistence of LYL797 CAR T cells in peripheral blood samples

    Time to last detectable LYL797, Tlast

    Time frame: Up to 2 years

07

Study locations

18 sites
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • University of California, Los Angeles
    Santa Monica, California 90404, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
  • Georgetown University
    Washington D.C., District of Columbia 20007, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • University of Miami
    Miami, Florida 33136, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • University of Oklahoma
    Oklahoma City, Oklahoma 73104, United States
  • Oregon Health and Science University Hospital
    Portland, Oregon 97239, United States
  • Sidney Kimmel Cancer Center, Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Sarah Cannon Research Institute and Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Froedtert Hospital, Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Nov 2024, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2022
First posted
Mar 10, 2022
StartActual
Mar 29, 2022
Primary completionActual
Nov 27, 2024
CompletionActual
Nov 27, 2024
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05274451
Lead sponsor
Lyell Immunopharma, Inc.
Responsible party
Sponsor
First posted
Mar 10, 2022
Start date
Mar 29, 2022
Primary completion
Nov 27, 2024
Completion
Nov 27, 2024
Last update
Jul 1, 2025

Study contacts

Jackie Walling, MBChB, PhD
study director · Lyell Immunopharma, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion